264 related articles for article (PubMed ID: 26729247)
1. A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.
Muz B; de la Puente P; Azab F; Luderer MJ; King J; Vij R; Azab AK
Br J Haematol; 2016 Apr; 173(1):70-81. PubMed ID: 26729247
[TBL] [Abstract][Full Text] [Related]
2. The potential diagnostic power of CD138+ microparticles from the plasma analysis for multiple myeloma clinical monitoring.
Liu ZY; Tian MY; Deng L; Wang YS; Xing R; Liu H; Fu R
Hematol Oncol; 2019 Oct; 37(4):401-408. PubMed ID: 31291481
[TBL] [Abstract][Full Text] [Related]
3. Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients.
Shires K; Wienand K
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2383-96. PubMed ID: 27581737
[TBL] [Abstract][Full Text] [Related]
4. Enrichment of circulating myeloma cells by immunomagnetic beads combined with flow cytometry for monitoring minimal residual disease and relapse in patients with multiple myeloma.
Wang N; Tesfaluul N; Li J; Gao X; Liu S; Yue B
Ann Hematol; 2019 Dec; 98(12):2769-2780. PubMed ID: 31748925
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor receptor 3 is a novel marker differing CD138-positive and CD138-negative multiple myeloma cells.
Kostjukova MN; Tupitsyn NN; Karamysheva AF
Br J Haematol; 2018 Jun; 181(6):840-843. PubMed ID: 28508400
[No Abstract] [Full Text] [Related]
6. Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.
Kawano Y; Kikukawa Y; Fujiwara S; Wada N; Okuno Y; Mitsuya H; Hata H
Int J Oncol; 2013 Dec; 43(6):1809-16. PubMed ID: 24126540
[TBL] [Abstract][Full Text] [Related]
7. The evaluation of minimal residual disease in multiple myeloma by fluorescent molecular beacons in real time PCR of IgH gene rearrangements and correlation with flow cytometry.
Kara IO; Duman BB; Afsar CU
J BUON; 2013; 18(2):442-7. PubMed ID: 23818359
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
[TBL] [Abstract][Full Text] [Related]
10. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
[TBL] [Abstract][Full Text] [Related]
11. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
12. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
13. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.
Puig N; Sarasquete ME; Alcoceba M; Balanzategui A; Chillón MC; Sebastián E; Marín LA; Díaz MG; San Miguel JF; Sanz RG
Ann Hematol; 2013 Jan; 92(1):97-100. PubMed ID: 22956183
[TBL] [Abstract][Full Text] [Related]
14. Effect of levamisole on expression of CD138 and interleukin-6 in human multiple myeloma cell lines.
Nageshwari B; Merugu R
Indian J Cancer; 2017; 54(3):566-571. PubMed ID: 29798960
[TBL] [Abstract][Full Text] [Related]
15. Double CD38
Mykytiv V; Alwaheed A; Mohd Hashim NA
Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):64-66. PubMed ID: 29079129
[TBL] [Abstract][Full Text] [Related]
16. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
17. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Matsui W; Wang Q; Barber JP; Brennan S; Smith BD; Borrello I; McNiece I; Lin L; Ambinder RF; Peacock C; Watkins DN; Huff CA; Jones RJ
Cancer Res; 2008 Jan; 68(1):190-7. PubMed ID: 18172311
[TBL] [Abstract][Full Text] [Related]
18. [Detection of multiple myeloma cells using multicolor immunofluorescence and flow cytometry].
Tousková M; Maisnar V; Krejsek J; Kopecký O
Vnitr Lek; 1999 Dec; 45(12):708-12. PubMed ID: 10951845
[TBL] [Abstract][Full Text] [Related]
19. [Effect of 2-methoxyestradiol on differentiation of primary myeloma cells].
Gao WR; Hou J; Xiong H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):262-6. PubMed ID: 16638193
[TBL] [Abstract][Full Text] [Related]
20. Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device.
Qasaimeh MA; Wu YC; Bose S; Menachery A; Talluri S; Gonzalez G; Fulciniti M; Karp JM; Prabhala RH; Karnik R
Sci Rep; 2017 Apr; 7():45681. PubMed ID: 28374831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]